Ticker

NanoViricides (NYSE-A:NNVC) earlier this week provided an update on the advancement of its broad-spectrum antiviral candidate NV-387, outlining progress in Mpox clinical development and confirming orphan drug designation filings for multiple indications. Speaking to Proactive, CEO Dr Anil Diwan said the company has completed the full clinical trial application required to initiate a Phase 2 study of NV-387 in the…

NanoViricides (NYSE-A:NNVC) earlier this week provided an update on the advancement of its broad-spectrum antiviral candidate NV-387, outlining progress in...

NanoViricides has provided an update on the development of its investigational antiviral NV-387, alongside the filing of its quarterly report for the fiscal quarter ending December 31, 2025. NanoViricides said it is preparing to advance NV-387 into a Phase II clinical trial for Monkeypox (MPox) in the Democratic Republic of Congo.

NanoViricides (NYSE-A:NNVC), a clinical-stage biotechnology company developing broad-spectrum antiviral therapies, has filed for Orphan Drug Designation (ODD) with the US Food and Drug Administration (FDA) for its lead candidate NV-387 as a treatment for MPox. If granted, the designation could provide NanoViricides with tax credits for clinical trials, exemption from certain user fees, and up to seven years of…

SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for Orphan Drug Designation (ODD) for "NV-387 as a…